Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Novel CD206 Targeting Peptide Inhibits Bleomycin Induced Pulmonary Fibrosis in MiceAnghesom Ghebremedhin, Ahmad Bin Salam, Benjamin Adu-Addai, et al.
Scientific Reports|December 22, 2022
MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African AmericansAnusha Angajala, Hughley Raymond, Aliyu Muhammad, et al.
Cancers|December 11, 2022
Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate CancerSuman Mazumder, Taraswi Mitra Ghosh, Ujjal K Mukherjee, et al.
Journal of Global Oncology|September 4, 2019
Pathology Services in Nigeria: Cross-Sectional Survey Results From Three Cancer ConsortiaPeter Ntiamoah, Ngozi R Monu, Fatimah B Abdulkareem, et al.
Cancers|May 17, 2020
Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race PopulationsMelissa Davis, Rachel Martini, Lisa Newman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 5, 2019
Atypical Chemokine Receptor 1 (<i>DARC/ACKR1</i>) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African AncestryBrittany D Jenkins, Rachel N Martini, Rupali Hire, et al.
Epigenomics|April 27, 2022
Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a reviewAliyu Muhammad, Gilead Ebiegberi Forcados, Babangida Sanusi Katsayal, et al.
NPJ Breast Cancer|August 8, 2025
Race-related host and microbe transcriptomic signatures in triple-negative breast cancerRoshan Kumar, Susan Duyar-Ayerdi, Aishwarya Sundaresan, et al.
Cancer Cell|August 20, 2021
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacyYujue Wang, Sixue Liu, Zhentao Yang, et al.
JCO Global Oncology|April 9, 2021
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN RegistryRana R McKay, Theresa Gold, Jelani C Zarif, et al.
Pageof 9